

1614  
\$  
75  
RECEIVED  
OCT 22 2002  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of  
T. Rogers

Serial No. 09/963,927

Filed: September 26, 2001

For: Hydroxy Acid Integrin Antagonists

)  
)Attorney Docket No. 3391/US  
)  
)Group Art Unit: 1614  
)  
)Examiner: Unknown

Assistant Commissioner of Patents  
Washington, D.C. 20231

SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit herewith a document cited on the attached Form PTO 1449. Applicants direct the Examiner to the related application(s) for documents previously submitted. Applicants respectfully request that the Examiner consider and enter the document cited on the enclosed Form PTO 1449 into the file of the above-identified application. Applicants also request an indication of the same by return of the Form PTO 1449 being initialed and dated by the Examiner.

Please charge the fee of \$180.00 as required by 37 C.F.R. § 1.17(p) to Deposit Account No. 19-1025. No additional fees are believed due to ensure consideration of the attached documents by the Examiner. However, if any additional fees are required or an overpayment of fees made, the Commissioner is hereby authorized to debit or credit our Deposit Account No. 19-1025, as necessary.

Respectfully submitted,



Rachel A. Polster, Agent  
Registration No. 47,004  
(314) 694-7354 (St. Louis)

Pharmacia Corporation  
Corporate Patent Department  
800 North Lindbergh Boulevard – O4E  
St. Louis, MO 63167



CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Serial No. 09/963,927  
Filing Date: September 26, 2001  
Examiner: Unknown  
Group Art Unit: 1614  
Docket No: 3391/US  
Invention: Hydroxy Acid Integrin Antagonists

Date of Deposit: October 17, 2002

I hereby certify that these papers or fee is being deposited with the United States Post Office to Addressee service under 37 CFR 1.10 & 1.8 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231

Information Disclosure Statement  
PTO-1449  
Copy of International Search Report  
Copy of References  
Fee Transmittal  
Return Post Card

Linda Haley  
(Typed or printed name of person mailing paper or fee)

Linda Haley  
(Signature of person mailing paper or fee)



Sheet 1 of 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: S03391	APPLICATION NO.: 09/963,927
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		INVENTOR: Thomas Rogers, et al.	
(Use several sheets if necessary)		Filed: Sept. 26, 2001	Group: 1614

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
1	5602155	02/11/1997	Ruminiski	514	357	01/17/1995
2	6013651	01/11/2000	Rogers, et al.	514	269	03/04/1998
3	6028223	02/22/2000	Ruminski, et al.	564	27	08/27/1996
4	6211191	04/03/2001	Duggan, et al.	514	274	12/15/1998

**FOREIGN PATENT DOCUMENTS**

Examiner Initial							Translation	
	Document Number	Date	Country	Class	Subclass	Yes	No	
5	WO 97/08145	06.03.1997	US	C07D	213/55	X		

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

Examiner Initial		
6	Carron, et al., <i>Cancer Research</i> ; V. 58, No. 9: pp 1930-1935; 1998	
7	Lark, et al., <i>Journal of Bone &amp; Mineral Research</i> ; V. 16, No. 2: pp 319-327; 2000	
8	Healy, et al., <i>Human Reproductive Update</i> ; V. 4: pp 136; 1998	
9	Cheresh, <i>Cancer Metastasis Review</i> ; V. 10: pp 3-10; 1991	
10	Brooks, et al., <i>Cell</i> ; V. 79, No. 7: pp 1157-1164; 1994	
11	Friedlander, et al., <i>Proceedings of the National Academy of Science USA</i> ; V. 93, No. 18; pp 9764-9769; 1996	
12	Badger, et al., <i>Arthritis &amp; Rheumatism</i> ; V. 44, No. 1: pp 128-137; 2001	
13	Brown, <i>Cardiovascular Research</i> ; V. 28: pp 1815-; 1994	
14	Friedlander, et al., <i>Science</i> ; V. 270 (5241): pp 1500-1502; 1995	
15	Agrez, et al., <i>Journal of Cell Biology</i> ; V. 127, No. 2: pp 547-556 ; 1994	
16	Christofidou-Solomidou, et. al., <i>American Journ. Of Pathology</i> ; V.151 (4): pp 975-983;1997	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP-609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**RECEIVED** (Form PTO-1449)

OCT 22 2002

TECH CENTER 1600/2900



Sheet 2 of 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: S03391	APPLICATION NO.: 09/963,927
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		INVENTOR: Thomas Rogers, et al.	
(Use several sheets if necessary)		Filed: Sept. 26, 2001	Group: 1614

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

Examiner Initial	
17	Seftor, et al., <i>Proceedings of the National Academy of Science USA</i> ; V. 89: pp 1557-1561; March 1992
18	Montgomery, et al., <i>Proceedings of the National Academy of Science USA</i> ; V. 91: pp 8856-8860; September 1994
19	Adamis, et al., <i>American Journal of Ophthalmology</i> ; V. 118: pp 445-450; 1994
20	Peacock, et al., <i>Journal of Experimental Medicine</i> ; V. 175: pp 1135-1138; 1992
21	Brooks, et al., <i>Science</i> ; V. 264: pp 569-571; 1994
22	Sato, et al., <i>Journal of Cell Biology</i> ; V. 111: pp 1713-1723; 1990
23	Fisher, et al., <i>Endocrinology</i> ; V. 132: pp 1411-1413; 1993
24	Choi, et al., <i>Journal of Vascular Surgery</i> ; V. 19 (1): pp 125-134; 1994
25	White, <i>Current Biology</i> ; V. 3 (9): pp 596-599; 1993
26	Rodriquez, et al., <i>Tetrahedron Letters</i> ; V. 32 (7): pp 923-926; 1991
27	Design in Prodrugs, H. Bundgaard, editor; Elsevier; 1985
28	Pytelka, et al., <i>Methods in Enzymology</i> , V. 144: pp 475-489; 1987
29	Yatohgo, et al., <i>Cell Structure &amp; Function</i> ; V. 13: pp 281-292; 1988
30	Charo, et al., <i>Journal of Biological Chemistry</i> , V. 266 (3): pp 1415-1421; 1991
31	Niya, et al., <i>Blood</i> , V. 70 (2): pp 475-483; 1987
32	Rodbard, et al., <i>International Atomic Energy Agency, Vienna</i> ; pp 469-; 1977
33	Zucker, <i>Methods in Enzymology</i> ; V. 169: pp 117-133; 1989

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

(Form PTO-1449)

**RECEIVED**

OCT 22 2002

TECH CENTER 1600/2900